CDKN2A and lung adenocarcinoma: In patients with stage IV lung adenocarcinoma, those who lacked CDKN2A expression in the primary tumor had longer overall survival than patients with normal CDKN2A expression (median 37.35 months vs. 23.61 months), but the difference was not significant (P = 0.119; Figure 5D).